Most Read This Week
- Outcomes of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and Clinical Subgroups
- Diagnostic Accuracy of ESR1 Mutation Detection in Breast Cancer Using Cell-Free DNA
- Safety of Alpelisib Combined With Capecitabine in Patients With HER2− Metastatic Breast Cancer
- Effect of PR Status on the Prognosis of Patients With Advanced ER-High HER2− Breast Cancer Receiving First-Line CDK4/6 Inhibitor Plus Endocrine Therapy
- Efficacy of CDK4/6 Inhibitors Plus Endocrine Therapy vs Placebo Plus Endocrine Therapy for HR+/HER2− Advanced Breast Cancer
Recently Updated
- Safety of Alpelisib Combined With Capecitabine in Patients With HER2− Metastatic Breast Cancer
- Efficacy of CDK4/6 Inhibitors Plus Endocrine Therapy vs Placebo Plus Endocrine Therapy for HR+/HER2− Advanced Breast Cancer
- Safety and Tolerability of the Next-Generation Oral SERD Camizestrant in Women With ER+/HER2− Advanced Breast Cancer
- Epidemiology of Early vs Late Recurrence Among Women With Early-Stage ER+ Breast Cancer
- Prognostic Value of the 21-Gene Breast Recurrence Score Assay for HR+/HER2− Advanced Breast Cancer